This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chow, C. C. Articles by Cockram, C. S. Search for Related Content PubMed PubMed Citation Articles by Chow, C. C. Articles by Cockram, C. S. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL

Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism

Departments of Medicine and Therapeutics (C.C.C., W.B.C., N.N.C., C.S.C.) and Chemical Pathology (M.H.M.C.), The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Department of Medicine, Yan Chai Hospital, Hong Kong (J.K.Y.L.); Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong (G.T.C.K.); and Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong (K.W.L.)

Address all correspondence and requests for reprints to: Dr. C. C. Chow, Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. E-mail: ccf193chow{at}cuhk.edu.hk.

The effect of biphosphonate therapy on bone mineral density (BMD) in patients with primary hyperparathyroidism (PHP) is unknown. Forty postmenopausal women (mean age, 70 yr) with PHP were randomized to receive alendronate 10 mg/d or placebo for 48 wk, followed by treatment withdrawal for 24 wk. The mean (±SD) changes in BMD at femoral neck (+4.17 ± 6.01% vs. -0.25 ± 3.3%; P = 0.011) and lumbar spine (+3.79 ± 4.04% vs. 0.19 ± 2.80%; P = 0.016) were significantly higher with alendronate at 48 wk. Serum calcium was reduced with alendronate but not placebo (-0.09 vs. +0.01 mmol/liter; P = 0.018). Serum bone-specific alkaline phosphatase activity was lower with alendronate from 12 wk onward and increased 24 wk after treatment withdrawal (21.1 ± 12.8 to 7.3 ± 4.9 IU/liter at 48 wk, and 15.0 ± 14.8 IU/liter 24 wk after withdrawal; P = 0.002 for trend). Osteocalcin concentration decreased at 48 wk and increased 24 wk after alendronate withdrawal (P = 0.019 for trend of change over time) but not with placebo. Urinary N-telopeptide/creatinine ratio decreased with alendronate at 48 wk and increased 24 wk after treatment withdrawal (P = 0.008 for trend). N-telopeptide/creatinine ratio did not change with placebo. Alendronate improves BMD and reduces bone turnover markers in postmenopausal women with PHP.

This study was supported in part by the Medical School Grant Program from Merck \|[amp ]\| Co., Inc.

Abbreviations: BMD, Bone mineral density; Bone-ALP, bone-specific alkaline phosphatase activity; CV, coefficient(s) of variation; HRT, hormone replacement therapy; PHP, primary hyperparathyroidism.

This article has been cited by other articles:

				A. Khan, A. Grey, and D. Shoback Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 373 - 381. [Abstract] [Full Text] [PDF]

				P Iglesias and J J Diez Current treatments in the management of patients with primary hyperparathyroidism Postgrad. Med. J., January 1, 2009; 85(999): 15 - 23. [Abstract] [Full Text] [PDF]

				N. Farag, T. Delbanco, and G. J. Strewler Update: A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, November 5, 2008; 300(17): 2044 - 2045. [Full Text] [PDF]

				F. R. SINGER and D. R. EYRE Using biochemical markers of bone turnover in clinical practice Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750. [Abstract] [Full Text] [PDF]

				E. Ambrogini, F. Cetani, L. Cianferotti, E. Vignali, C. Banti, G. Viccica, A. Oppo, P. Miccoli, P. Berti, J. P. Bilezikian, et al. Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3114 - 3121. [Abstract] [Full Text] [PDF]

				B. Farford, R. J. Presutti, and T. J. Moraghan Nonsurgical Management of Primary Hyperparathyroidism Mayo Clin. Proc., March 1, 2007; 82(3): 351 - 355. [Abstract] [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				M. Peacock, J. P. Bilezikian, P. S. Klassen, M. D. Guo, S. A. Turner, and D. Shoback Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 135 - 141. [Abstract] [Full Text] [PDF]

				A. A. Khan, J. P. Bilezikian, A. W. C. Kung, M. M. Ahmed, S. J. Dubois, A. Y. Y. Ho, D. Schussheim, M. R. Rubin, A. M. Shaikh, S. J. Silverberg, et al. Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3319 - 3325. [Abstract] [Full Text] [PDF]

				J. P. Bilezikian and S. J. Silverberg Asymptomatic Primary Hyperparathyroidism N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751. [Full Text] [PDF]